{"entity":{"id":"nct05286957","kind":"trial","name":"MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC","aka":["Seagull"],"tldr":"A phase 2 trial in lung cancer, run by The First Affiliated Hospital of Zhengzhou University, now recruiting.","summary":"MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC is a phase 2, randomised interventional study registered as NCT05286957 by The First Affiliated Hospital of Zhengzhou University, with a registry enrolment figure of 60 participants, started 2022-06-20 and due to reach its primary completion in 2026-06-01. Interventions recorded: adjuvant tislelizumab and chemotherapy for MRD+ patients; adjuvant tislelizumab and chemotherapy for MRD+ patients; adjuvant chemotherapy for MRD- patients. Conditions listed: NSCLC. Primary outcome: 2-year PFS rate. Lung eligibility wording from the registry: \"Histologically confirmed primary NSCLC, postoperative stage is IIA, IIB, IIIA or T3N2IIIB\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT05286957","url":"https://clinicaltrials.gov/study/NCT05286957"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["resectable-nsclc"],"sections":[],"technologies":["mrd-testing"],"targets":[],"drugs":[],"companies":["beone"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05286957","phase":"2","setting":"Minimal Residual Disease (MRD)-Guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB Non-small Cell Lung Cancer (NSCLC): a Randomized Controlled Phase II Study (Seagull)","sponsor":"The First Affiliated Hospital of Zhengzhou University","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05286957/","neighbours":{"cancer":[{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"company":[{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}